^
Association details:
Biomarker:No biomarker
Cancer:Colorectal Cancer
Drug:Avzivi (bevacizumab-tnjn) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
12/06/2023
Excerpt:
Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of:...Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment...Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
Secondary therapy:
5-fluorouracil; oxaliplatin; irinotecan